The company has reported zero revenue across the last ten quarters, while R&D expenses reached a peak of $11.6 million in 2024Q4, highlighting the heavy financial burden of its clinical pipeline.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 2.69M | 2.92M | 1.8M | 871K | 0 | 0 | 0 | 0 | 210K | 95K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -2.69M | -2.92M | -1.8M | -871K | 0 | 0 | 0 | 0 | -210K | -95K |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -62.06% | -107% | - | - | - | - | 100% | -121.05% | - |
| Operating Expenses | 21.77M | 29.99M | 37.22M | 26.81M | 27.22M | 35.46M | 30.26M | 22.21M | 12.93M | 7.28M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 8.73M | 6.71M | 11.78M | 7.78M | 9.46M | 11.27M | 9.99M | 8.72M | 3.36M | 2.54M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 15.73M | 23.28M | 24.66M | 19.04M | 16.24M | 22.68M | 21.61M | 13.96M | 9.57M | 4.74M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -2.29M | 0 | 785K | 0 | 1.52M | 1.52M | -1.34M | -466K | 0 | 0 |
| Operating Income | -24.46M | -32.91M | -39.03M | -27.68M | -27.22M | -35.46M | -30.26M | -22.21M | -13.14M | -7.37M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 15.67% | -40.97% | -1.71% | 23.24% | -17.2% | -36.25% | -68.99% | -78.26% | - |
| EBITDA | -39.43M | -29.99M | -37.22M | -26.81M | -24.7M | -32.9M | -29.6M | -21.89M | -12.93M | -7.28M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -314.44% | 19.44% | -38.82% | -8.56% | 24.92% | -11.15% | -35.21% | -69.28% | -77.7% | - |
| D&A (Non-Cash Add-back) | 2.69M | 2.92M | 1.8M | 871K | 2.52M | 2.56M | 662K | 318K | 210K | 95K |
| EBIT | -47.22M | -35.21M | -14.93M | -23.69M | -26.18M | -35.46M | -30.26M | -22.21M | -12.72M | -6.43M |
| Net Interest Income | -827K | -524K | -1.74M | -1.28M | -1.17M | -697K | 634K | 857K | 0 | 0 |
| Interest Income | 0 | 460K | 1.05M | 1.12M | 902K | 2K | 641K | 921K | 0 | -21K |
| Interest Expense | 827K | 984K | 2.79M | 2.4M | 2.07M | 699K | 7K | 64K | 0 | 0 |
| Other Income/Expense | -23.21M | -3.28M | 21.31M | 1.54M | -1.03M | -697K | 172K | 1.64M | 421K | 939K |
| Pretax Income | -47.67M | -36.19M | -17.71M | -26.15M | -28.25M | -36.16M | -30.09M | -20.56M | -12.72M | -6.43M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 6K | 7K | 13K | 23K | 65K | 67K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.01% | -0.02% | -0.07% | -0.09% | -0.23% | -0.19% | 0% | 0% | 0% | 0% |
| Net Income | -47.68M | -36.2M | -17.73M | -26.17M | -28.32M | -36.23M | -30.09M | -20.56M | -12.72M | -6.43M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -277.39% | -104.2% | 32.26% | 7.59% | 21.83% | -20.41% | -46.31% | -61.66% | -97.73% | - |
| Net Income (Continuing) | -47.68M | -36.2M | -17.73M | -26.17M | -28.32M | -36.23M | -30.09M | -20.56M | -12.72M | -6.43M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.02 | -22.19 | -27.93 | -96.90 | -180.31 | -264.67 | -24.70 | -15.96 | -122.74 | -62.13 |
| EPS Growth % | 19.32% | 20.55% | 71.18% | 46.26% | 31.87% | -971.54% | -54.76% | 87% | -97.55% | - |
| EPS (Basic) | - | -22.19 | -27.93 | -96.90 | -180.31 | -264.67 | -24.70 | -15.96 | -122.74 | -62.13 |
| Diluted Shares Outstanding | 2.6B | 1.63B | 691.48M | 2.7M | 1.57M | 1.37M | 1.21M | 1.19M | 1.05M | 1.04M |
| Basic Shares Outstanding | 2.6M | 69.81M | 3.67M | 2.7M | 1.57M | 1.37M | 1.21M | 1.19M | 1.05M | 1.04M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Critical liquidity and dilution
As indicated by the company's financial disclosures, BiomX has reported zero revenue across the last ten quarters, confirming its status as a purely clinical-stage entity that remains entirely dependent on external capital markets to fund its ongoing research and development activities for its phage-based therapeutic pipeline.
The absence of top-line growth highlights the company's reliance on milestone-driven development rather than commercial operations. Investors should monitor the transition from R&D to potential licensing revenue, as the current lack of sales underscores the high-risk nature of the firm's long-term viability.
Based on the provided income statement data, R&D expenses have fluctuated significantly, peaking at $11.6 million in 2024Q4, which reflects the heavy financial burden of advancing clinical trials and maintaining the proprietary BOLT platform amidst a challenging environment for early-stage biotechnology firms seeking sustained operational funding.
The volatility in R&D spending suggests a project-based cost structure that is highly sensitive to clinical trial milestones. Management's ability to control these expenses while maintaining progress on the BX004 program remains a critical factor for the company's limited cash runway.
According to the reported financial statements, net income figures exhibit extreme volatility, including a $5.1 million gain in 2024Q3, which appears to be driven by non-operating items such as warrant liability revaluations rather than any underlying improvement in the company's core operational or commercial performance metrics.
These accounting fluctuations mask the true cash burn rate and complicate the assessment of operational efficiency. Analysts should strip out these non-cash adjustments to better understand the underlying financial health and the actual rate at which the company is consuming its limited capital reserves.
With a reported cash position of approximately $4.95 million, the company faces a precarious financial situation that warrants significant caution, as the current burn rate suggests that existing capital may be insufficient to support the necessary clinical development timelines without further dilutive equity financing events.
The reliance on equity issuance at potentially depressed valuations poses a substantial risk to existing shareholders. The market may be underestimating the urgency of the company's capital needs, which could lead to significant dilution if management is unable to secure non-dilutive funding or strategic partnerships.
Quick answers to the most common questions about buying PHGE stock.
For fiscal year 2025, BiomX Inc. (PHGE) reported total revenue of $0.0M.
BiomX Inc. (PHGE) reported a net loss of $36.2M for the fiscal year ending 2025.